Item 7.01 Regulation FD Disclosure.

On January 27, 2022, Provention Bio, Inc. issued a press release related to its Type B pre-Biologics License Application ("BLA") resubmission meeting with the U.S. Food & Drug Administration and planned resubmission of a BLA for teplizumab. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this report furnished pursuant to Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.

Item 9.01 Financial Statements and Exhibits.

(d) The following exhibit is furnished with this report:





Exhibit No.   Description

99.1            Press Release issued by Provention Bio, Inc. on January 27, 2022
104           Cover Page Interactive Data File (formatted as Inline XBRL)

© Edgar Online, source Glimpses